Generally, Alzheimer's disease affects eldery population, and there are some patients who have difficulty swallowing a tablet or granule formulation with water due to the decline in their ability to swallow or the water enters into their trachea while taking the medication... Eisai's Press Release -
Blog Archive
-
▼
2008
(79)
-
▼
March
(11)
- ExonHit, EHT 0202 Counters Scopolamine's Detriment...
- Cryo-Cell International : Umbilical Cord Blood Cel...
- Evotec's EVT 101 : to Penetrate the Brain in Man a...
- Eisai, Application for Aricept Oral Jelly Formulat...
- Neurobiological Technologies and Buck Institute, t...
- Bar Harbor BioTechnology : New Line of StellARrays
- Power3 Medical , Three Hundred Patient Clinical Va...
- Pharmatrophix Alzheimer's Drug Discovery Foundatio...
- Hunter-Fleming and Newron, continuation of phase I...
- Debiopharm's Debio 9902 SR in Alzheimer’s disease,...
- Power3 Medical, Patent Application for Forty-Seven...
-
▼
March
(11)
Friday, March 21, 2008
Eisai, Application for Aricept Oral Jelly Formulation in Japan
Generally, Alzheimer's disease affects eldery population, and there are some patients who have difficulty swallowing a tablet or granule formulation with water due to the decline in their ability to swallow or the water enters into their trachea while taking the medication... Eisai's Press Release -